Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

American Crew

This article was originally published in The Rose Sheet

Executive Summary

Colomer Group licenses AHK Copper Peptide Complex technology from ProCyte to develop hair care products for men and women with thinning hair under American Crew brand, ProCyte says. Although ProCyte currently markets copper peptide-formulated hair care brand Tricomin to dermatologists and cosmetic surgeons, American Crew brand will be distributed through firm's 35,000-door salon network. Neutrogena recently launched Visibly Firm skin care products formulated with ProCyte's copper peptide technology (1"The Rose Sheet" Feb. 26, p. 4)

You may also be interested in...



Neutrogena Visibly Firm Takes Elemental Approach With Active Copper

Neutrogena Visibly Firm Night and Eye creams employ the nutrient copper to restore skin firmness and regain measurably smooth, buoyant skin, the Johnson & Johnson division said at a press event in New York City Feb. 20.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel